IBM Watson, Quest Diagnostics, Memorial Sloan Kettering partner for cancer research
Through the service, physicians will be able to send a patient's tumor tissue to Quest Diagnostics for genetic sequencing. IBM Watson will then analyze the genetic alterations in the tissue, and Memorial Sloan Kettering will conduct a research-based analysis through its oncology precision medicine database to determine potential treatment options.
Through the collaboration, the partners hope to give physicians "the ability to create a unique, personalized approach for their patients," according to IBM.
More articles on health IT:
USAID funds technology platform to identify Zika "cold spots" in Guatemala
Eastern Oklahoma VA, local healthcare organizations to share veteran health information through eHealth Exchange
Mobile health app revenue expected to grow through 2020: 4 things to know
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.